Sintilimab: A Promising Anti-Tumor PD-1 Antibody

Abstract

Sintilimab (Tyvyt®) is a monoclonal antibody against programmed cell death protein 1 (PD-1). It could block the interaction between PD-1 and its ligands and help the anti-tumor effect of T-cells to recover. Sintilimab is developed by Innovent Biologics and Eli Lilly and Company and has been approved to treat relapsed or refractory classical Hodgkin lymphoma in patients who have undergone two or more lines of systemic chemotherapy by the National Medical Products Administration of China. Recently, sintilimab has been reported in plenty of literature and shows satisfying anti-tumor effect. Meanwhile, there are some reports showing its side effects. Overall, sintilimab has similar anti-tumor effects and a better safety profile compared to nivolumab and pembrolizumab in Hodgkin lymphoma, natural killer/T cell lymphoma and advanced non-small cell lung cancer. In this review, we aim to briefly describe the mechanisms, pharmacological characteristics, anti-tumor effects, predictive parameters of efficacy and side effects of sintilimab, providing valuable information of sintilimab for decision-making in the treatment of tumors in the future.

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report

“…21 In a multicenter, phase Ib trial (NCT02937116), treatment was safe and well tolerated with a satisfying efficacy in patients who received sintilimab. 22 In T A B L E 1 Cytokine profile and reference value results…”

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?

“…The PD-1/PD-L1 axis is a vital checkpoint in tumor progression and immune evasion. The binding of PD-1 to PD-L1 resulted in T cell anergy, exhaustion, apoptosis, and reduced cytotoxicity ( 5 ). The drug mechanisms of anti- PD-1/PD-L1 antibodies are similar.…”

“…Anti-PD-1 antibodies have been approved for use in various solid tumors and lymphomas ( 7 ). A multicenter, single-arm, phase II trial of sintilimab to treat relapsed or refractory classical Hodgkin’s lymphoma (cHL) was carried out in China and showed that the overall response rate (ORR) was 80.4% ( 5 , 8 ). Single sintilimab therapy also revealed an anti-tumor effect in extranodal natural killer (NK)/T cell lymphoma (ENKTL) in a phase II trial ( 5 ).…”

“…Single sintilimab therapy also revealed an anti-tumor effect in extranodal natural killer (NK)/T cell lymphoma (ENKTL) in a phase II trial ( 5 ). The ORR was 67.9% and the disease control rate was 85.7% ( 5 ). Sintilimab combined with decitabine and the histone deacetylase inhibitor chidamide resulted in partial remission in DLBCL ( 9 ).…”

“…Sintilimab combined with decitabine and the histone deacetylase inhibitor chidamide resulted in partial remission in DLBCL ( 9 ). Phase II studies have revealed that the ORR after treatment with either nivolumab or pembrolizumab was 66.3% and 69.0%, respectively, in patients with relapsed or refractory cHL ( 5 , 10 , 11 ). The ORR of pembrolizumab in patients with ENKTL was 78.6% ( 12 ).…”